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Abstract
Background: “Inflammaging” is a coined term that combines the processes of inflammation (within the normal
range) and aging, since chronic, low-grade, systemic inflammation emerges with increasing age. Unlike high-level
inflammation, with which deleterious effects on bone no longer need to be demonstrated, it is unclear whether
inflammaging exerts deleterious effects on bone too.
Method: We assessed associations between inflammaging — measured via cytokine levels (high-sensitivity C-
reactive protein (hs-CRP); interleukin-1β (IL-1β); interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α)) — and bone
parameters (prevalent and incident fractures, bone mineral density (BMD) and trabecular bone score (TBS)) in 1390
postmenopausal women from the OsteoLaus study.
Results: Mean (±SD) age was 64.5 ± 7.6 and mean bone mass index (BMI) 25.9 ± 4.5 kg/m2. Median hs-CRP, IL-1β, IL-6
and TNF-α were 1.4 pg/ml, 0.57 pg/ml, 2.36 pg/ml and 4.82 pg/ml, respectively. In total, 10.50% of the participants had a
prevalent, low-impact fracture; and, after 5-years of follow up, 5.91% had an incident, low-impact fracture. Mean T-score
BMD was − 1.09 ± 1.53 for the spine, − 1.08 ± 1.02 for the femoral neck, and − 0.72 ± 0.96 for the total hip. Mean spine TBS
was 1.320 ± 0.10. We found a positive association between hs-CRP and BMD at all sites, and between hs-CRP and the TBS,
but none of these associations were significant after adjustment. We found no association between prevalent or incident
fractures and hs-CRP. No association was found between IL-1β, IL6 and TNF-α and BMD, TBS or fractures.
Conclusion: Our results suggest that bone imaging and structure parameters are not associated with the low-grade
cytokine levels (within the normal range) observed with inflammaging.
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Summary
In this large population-based cohort, we did not find a re-
lation between the coined concept of “inflammaging” (hs-
CRP, IL-6, IL-1β and TNF-α within the normal range)
and bone parameters, measured in terms of prevalent and
incident fractures, bone mass density and trabecular bone
score.
Background
The “network theory of aging” argues that a concomitant
progressive increase in proinflammatory status is a major
characteristic of the aging process. This phenomenon is
also referred to as “inflammaging”, which is a coined term
merging “inflammation” and “aging”. The term was first
proposed by Francheschi in 2000 to describe the low-
grade (inflammatory cytokines within the normal range),
chronic, systemic inflammation associated with the pro-
gressive stimulation/depletion of the immune system that
occurs with aging, in the absence of overt infection [1–3].
In addition to inflammatory cytokines — like tumor
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necrosis factor-alpha (TNF-α) [4], interleukin-6 (IL-6) and
interleukin-1 (IL-1) — being shown to increase with age,
so have serum levels of inflammatory parameters like C-
reactive protein (CRP) [5], with some parameters like CRP
and IL-6 increasing as early as the third or fourth decade
of life [6].
Several studies have linked inflammaging to patholo-
gies like atherosclerosis, type 2 diabetes mellitus, vascu-
lar disease, Parkinson’s disease, dementia, Alzheimer’s
disease and chronic obstructive pulmonary disease
(COPD) [4, 6–9]. Osteoporosis (OP) and fragility frac-
tures are more prevalent in inflammatory diseases, par-
ticularly rheumatoid arthritis (RA), systemic lupus
erythematosus (SLE) and COPD, when compared to the
healthy population [10]. These findings suggest that
chronic low elevations of circulating cytokines contrib-
ute to the development of OP [4, 6–9]. The immune sys-
tem plays an important role in bone remodeling, and
proinflammatory cytokines (IL-6, TNF-α and IL-1)
stimulate bone resorption in vitro [10, 11]. Experimental
studies in animals suggest that some inflammatory cyto-
kines — including IL-1, IL-6 and TNF-α — play an im-
portant role in the pathogenesis of OP [12].
Osteoporosis, a major health concern in all developed
countries [13, 14], is characterized by low bone mineral
density (BMD) and microarchitectural deterioration (as
measured by the trabecular bone score, TBS [13, 15]),
resulting in increased bone fragility. Eighty percent of in-
dividuals with OP are women, largely due to the marked
loss in BMD that begins at menopause, secondary to the
marked decrease in estrogen related to the loss of ovar-
ian function [16]. Moreover, estrogen plays a key role in
regulating the production and activity of inflammatory
cytokines like IL-1, IL-6 and TNF-α [17]. In recent years,
several studies have been conducted to establish a link
between proinflammatory cytokines and OP, but their
results are conflicting: some found a positive association
between inflammatory cytokines and OP [17–19] while
in other studies these associations have been inconsist-
ent [20–22].
Since 2010, we have been conducting a prospective
study, called OsteoLaus, to determine bone parameters:
fractures, BMD and TBS in postmenopausal women liv-
ing in Lausanne, Switzerland, and identify the determi-
nants of bone loss and bone fragility [23]. The primary
aim of the present study was to explore in a population
without clinically meaningful inflammation disease the
effect of hs-CRP, and secondary aim three others inflam-
matory parameters —, IL-6, IL-1β and TNF-α — on
bone parameters: evaluated in terms of prevalent and in-
cident low-impact fractures, BMD and TBS in the
OsteoLaus population. In others words, if in a normal
population with normal cytokines levels, the inflamma-
ging was related to bone health degradation.
Materials and methods
Recruitment
The OsteoLaus cohort is a sub-study of the CoLaus/PsyCo-
Laus study, an ongoing prospective study aiming to assess
the determinants of cardiovascular diseases using a
population-based sample drawn from the city of Lausanne,
Switzerland. The methods of both studies have been pub-
lished previously [23–25]. The aim of OsteoLaus is to
cross-sectionally and prospectively (follow-up every 2.5
years) compare different models of fracture risk prediction,
and to see how information on micro-architecture could ei-
ther improve or explain the differences between these
models. Between September 2009 and September 2012, all
women between 50 and 80 years old at the first CoLaus/
PsyCoLaus follow-up visit were invited to participate 6
months later in OsteoLaus. Of the initial 1704 participants
invited, 1500 (88%) accepted. Of these, 1475 women were
included in the OsteoLaus baseline visit, while 1234 partici-
pated 5 years later in the second OsteoLaus follow-up visit.
For this study, we used cytokines measured during the first
follow-up CoLaus/PsyCoLaus study, bone data from the
baseline OsteoLaus study, and incident fractures listed at
the second OsteoLaus follow-up visit.
Lifestyle, clinical and radiological data, fractures
At baseline, each patient completed a questionnaire about
their potential clinical risk factors for fracture/osteopor-
osis, according to the Swiss Fracture Risk Assessment
Tool -FRAX® assessment-, including conditions with po-
tential effects on bone metabolism and immunosuppres-
sant treatments like disease-modifying antirheumatic
drugs (DMARDS) or other biological therapies. Patients
had one spine (L1 to L4) and one femoral measurement
using the Discovery A System (Hologic, Waltham, MA,
USA), blinded central processing of TBS (TBS iNsight
v3.0, Medimaps, Merignac, France) based on a previously-
acquired AP spine DXA scan, and a vertebral fracture
(VFA) assessment using the semi-quantitative approach of
HK Genant [26].
Based on the literature, we consider a TBS of more than
1.31 normal; a TBS between 1.23 and 1.31 indicative of
partially-degraded bone architecture; and a TBS less than
1.23 indicative of degraded architecture [15, 27, 28].
We considered only major osteoporotic fractures, in-
cluding at least one fracture of a vertebra (clinical or
radiologic from grade 2/3 on a vertebral fracture assess-
ment), hip, pelvis, humerus or radius, either occurring
spontaneously or after a fall from ≤ standing height.
Cytokine measurements
Venous blood samples (50ml) were drawn in a fasting
state. Serum was preferred to plasma, as it has been shown
that different anticoagulants may affect absolute cytokine
levels differently. hs-CRP was assessed by immunoassay
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and latex HS (IMMULITE 1000-High, Diagnostic Prod-
ucts Corporation, LA, CA, USA) with maximum intra-
and inter-batch coefficients of variation of 1.3 and 4.6%,
respectively. Serum samples were kept at − 80 °C before
assessing IL-1β, IL-6 and TNF-α and sent in dry ice to the
laboratory. Cytokine levels were measured using a multi-
plexed particle-based flow cytometric cytokine assay, a
methodology used in other studies [29]. Milliplex kits
were purchased from Millipore (Zug, Switzerland). The
procedures closely followed the manufacturer’s instruc-
tions. The analysis was conducted using a conventional
flow cytometer (FC500 MPL, Beckman Coulter, Nyon,
Switzerland). Lower detection limits for IL-1β, IL-6 and
TNF-α were 0.2 pg/ml. Good agreement between signal
and cytokine was found within the assay range (R2 ≥ 0.99).
Intra and inter-assay coefficients of variation were 15 and
16.7% for IL-1β, 16.9 and 16.1% for IL-6, and 12.5 and
13.5% for TNF-α, respectively.
Inclusion and exclusion criteria
All participants with at least one BMD and TBS meas-
urement, one questionnaire and one cytokine measure-
ment were eligible for inclusion. To maintain
inflammatory levels close to the general population,
major exclusion criteria were the following: any disease
known to affect bone metabolism (neoplasia, inflamma-
tory bowel disease, RA, SLE, ankylosing spondylitis and
psoriatic arthritis), drugs taken by subjects known to
have an effect (negative or positive) on bone metabolism,
and a bone mass index (BMI) either less than 16 or
above 40.
Statistical analysis
Statistical analysis was conducted using Stata version 14.2
(StataCorp, College Station, TX, USA). We divided cytokine
results into quartiles. Univariable and multivariable analyses
were used to examine the associations between the inflam-
matory and bone parameters: fractures, BMD and TBS. For
bivariable analysis, we used chi-square or Fisher’s exact test
for categorical variables and analysis of variance (ANOVA)
for continuous variables. For multivariable analysis, we used
logistic regression for categorical variables and analysis of
variance (ANOVA) for continuous variables. Multivariable
models were adjusted for age (continuous), body mass index
(continuous), diabetes (yes/no), smoking (never/former/
current), alcohol consumption (none/1–20/21+ units/week),
current calcium treatment (yes/no) and current hormone
replacement therapy (HRT) status (yes/no). Statistical sig-
nificance was considered for a two-sided test with p < 0.05.
Results
Clinical characteristics of participants
Of the 1475 initial participants, 77 (5.2%) were excluded: 49
(3.3%) due to a corticoid, immuno-suppressant treatment
or chronic inflammatory disease, and 28 (1.9%) because of
missing data for at least one of the inflammatory parameter.
In addition, 8 (0.5%) were excluded because of a BMI less
than 16 or above 40. The clinical characteristics of included
and excluded participants are summarized in Table 1. No
significant differences were found between groups for any
variable studied, except for calcium and vitamin D supple-
ments, HRT, and other osteoporosis treatments.
Among the 1390 included participants, mean (±SD)
age was 64.5 ± 7.6, and mean BMI was 25.9 ± 4.5 kg/
Table 1 Comparison between excluded and included participants
Included (N = 1390) Excluded (N = 77) P-value
Age (years) 64.5 ± 7.6 63.7 ± 7.8 0.379
Body mass index (kg/m2) 25.9 ± 4.5 26.3 ± 4.7 0.440
Smoking (%) 0.425 §
Never 650 (46.8) 25 (41.7)
Former 503 (36.2) 21 (35)
Current 237 (17.1) 14 (23.3)
Alcohol consumption (%) 0.381 §
None 409 (29.4) 27 (35.1)
1–20 units/week 956 (68.8) 50 (64.9)
21+ units /week 25 (1.8) 0 (0)
Diabetes (%) 67 (4.8) 6 (8.2) 0.797
Osteoporosis (any location) 139 (10.0) 10 (13.0) 0.713
Calcium and vitamin D (%) 497 (35) 45 (58) < 0.001
Hormone replacement therapy (%) 323 (23) 9 (11) 0.018
Other current OP treatment (%) 58 (4.2) 12 (15.5) < 0.001 §
OP, osteoporosis. Results are expressed as number of participants (column %) or as mean ± standard deviation. Statistical analysis performed using chi-square or
Fisher’s exact test (§) for categorical variables and student’s t-test for continuous variables
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m2; 10.50% had a prevalent low-impact fracture.
Mean BMD was 0.925 ± 0.163 g/cm2 for the spine (T
score − 1.09 ± 1.53), 0.728 ± 0.114 g/cm2 for the fem-
oral neck (T score − 1.08 ± 1.02) and 0.854 ± 0.118 g/
cm2 for the total hip (T score − 0.72 ± 0.96); mean
spine TBS was 1.320 ± 0.10. During the second
follow-up visit, 5.91% of the analyzed participants had
a non-traumatic or low-impact fracture.
Association between bone imaging and structure
parameters and cytokine levels
We found a positive association between the BMD at all
sites, the TBS, and hs-CRP in univariable analyses (Table 2).
However, none of these associations remained significant
after adjusting for age, smoking, BMI, diabetes, alcohol con-
sumption, HRT, calcium and vitamin D or other osteopor-
osis treatments. We identified no association between
fractures and levels of hs-CRP (Table 2).
We found no association between IL-1β, IL6 or TNF-
α and bone parameters (fractures, BMD or TBS) either
before or after adjustment (Tables 3, 4, 5).
Discussion
In our population without clinically meaningful inflam-
mation disease, a cohort of 1390 postmenopausal
women, we found no association between cytokine levels
and bone parameters assessed by BMD, TBS or preva-
lent or 5-year incident fragility fractures.
Table 2 Bone parameters (fracture, BMD and TBS) according to quartiles of hs-CRP
First Second Third Fourth P-valuea P-value trend testb P-value adjustedc
N 349 347 352 335
hs-CRP, median [IQR] 0.5 [0.3–0.6] 1.0 [0.9–1.3] 2.0 [1.7–2.3] 4.8 [3.6–7.2]
Traumatic fracture (%) 89 (25.5) 79 (22.7) 108 (30.6) 82 (24.4) 0.096 0.973
Major osteoporotic fracture (%) 31 (8.8) 43 (12.4) 41 (11.6) 31 (9.2) 0.345 0.748
Incident 5 years fractures 15/339 (4.4) 24/339 (7.1) 23/343 (5.2) 17/325 (5.2) 0.415 0.147
Spine average BMD 0.901 ± 0.154 0.916 ± 0.166 0.928 ± 0.158 0.957 ± 0.169 0.001 < 0.001 0.625
Spine average T-score −1.32 ± 1.45 − 1.17 ± 1.56 − 1.1 ± 1.49 − 0.78 ± 1.59 < 0.001 < 0.001 0.717
Spine average TBS 1.304 ± 0.100 1.318 ± 0.102 1.326 ± 0.098 1.336 ± 0.107 0.0006 < 0.001 0.231
Femoral neck BMD 0.717 ± 0.116 0.718 ± 0.113 0.729 ± 0.104 0.752 ± 0.120 0.0002 < 0.001 0.781
Femoral neck T-score −1.18 ± 1.04 −1.17 ± 1.02 −1.08 ± 0.94 −0.87 ± 0.18 0.0002 < 0.001 0.809
Femur total BMD 0.835 ± 0.114 0.845 ± 0.116 0.858 ± 0.115 0.879 ± 0.125 < 0.001 < 0.001 0.895
Femur total T-score −0.88 ± 0.93 −0.79 ± 0.94 − 0.69 ± 0.93 −0.51 ± 1.02 < 0.001 < 0.001 0.823
Results are expressed as number of participants (%) or as mean ± standard deviation. Statistical analysis performed using chi-square for categorical variables and
ANOVA for continuous variablesa, p of trendb and after multiple adjustmentc (age, BMI, smoker, diabetes, alcohol, calcium, HRT)
Table 3 Bone parameters (fracture, BMD and TBS) according to quartiles of interleukin 1β
First Second Third Fourth P-valuea P-value trend testb P-value adjustedc
N 381 279 329 329
Interleukin 1β, median [IQR] undetectables 0.32 [0.25–0.43] 1.13 [0.84–1.50] 5.86 [3.02–12.8]
Traumatic fracture (%) 98 (25.7) 87 (31.1) 85 (25.8) 75 (22.8) 0.131 0.275
Major osteoporotic fracture (%) 54 (14.1) 27 (9.68) 30 (9.1) 31 (9.4) 0.090 0.176
Incident fracture 5 years 25/374 (6.6) 18/272 (6.6) 12/318 (3.7) 20/320 (6.2) 0.341 0.368
Spine average BMD 0.918 ± 0.163 0.937 ± 0.175 0.940 ± 0.157 0.910 ± 0.161 0.057 0.626 0.606
Spine average T-score −1.16 ± 1.55 −1.00 ± 1.62 −0.94 ± 1.47 − 1.21 ± 1.52 0.07 0.773 0.801
Spine average TBS 1.318 ± 0.108 1.323 ± 0.108 1.329 ± 0.098 1.316 ± 0.095 0.339 0.941 0.329
Femoral neck BMD 0.724 ± 0.110 0.740 ± 0.125 0.732 ± 0.109 0.725 ± 0.115 0.257 0.903 0.683
Femoral neck T-score −1.12 ± 0.99 −0.98 ± 1.12 −1.05 ± 0.98 − 1.11 ± 1.03 0.289 0.947 0.721
Femur total BMD 0.848 ± 0.118 0.860 ± 0.126 0.862 ± 0.116 0.851 ± 0.112 0.333 0.664 0.918
Femur total T-score −0.77 ± 0.96 − 0.67 ± 1.03 −0.65 ± 0.94 − 0.74 ± 0.91 0.342 0.735 0.998
Results are expressed as number of participants (%) or as mean ± standard deviation. Statistical analysis performed using chi-square for categorical variables and
ANOVA for continuous variablesa, p of trendb and after multiple adjustmentc (age, BMI, smoker, diabetes, alcohol, calcium, HRT)
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Relationship between bone imaging and structure
parameters and hs-CRP
Our study showed no difference in fractures, BMD or TBS
across the different quartiles of hs-CRP. CRP is the most
studied inflammatory marker. Several studies have shown
that hs-CRP is associated with lower BMD and/or an in-
creased risk of fracture [12, 17, 18, 20, 21, 28, 30, 31], but
others have failed to detect significant associations [20, 22,
30, 32, 33]. In the Geelong Osteoporosis study [30], frac-
ture risk increased by 24–32% for each SD increase in
CRP independently of BMD, prevalent vertebral fractures
and bone turnover parameters. In the Rotterdam study,
Oei et al. [32] showed that hs-CRP was associated with in-
cident fracture risk when men and women were analyzed
together. However, this association just reached statistical
significance for females (HR = 1.05, 95 IC 1.00–1.11, p =
0.05), and was more significant in the oldest age category
(> 73 years) and for a BMI between 24.5 and 27.5 kg/m2.
Our participants were younger. Cauley et al. [19] found a
37% increased risk of fracture in the highest tertile of CRP
(> 3.14mg/l); but, after adjustment, this association did
not retain significance (HR = 1.34, 95% IC 0.99–1.82).
Therefore, the population was over 70 years old, 48.5%
male and 42% black. Finally, in studies in which a positive
Table 4 Bone parameters (fracture, BMD and TBS) according to quartiles of interleukin 6
First Second Third Fourth P-
valuea
P-value trend
testb
P-value
adjustedc
N 333 330 326 329
Interleukin 6, median [IQR] 0.41 [0.22–
0.63]
1.52 [1.19–
1.87]
3.84 [2.98–
5.30]
22.01 [12.33–
61.31]
Traumatic fracture (%) 76 (22.8) 99 (30.0) 80 (24.5) 91 (27.6) 0.155 0.497
Major osteoporotic fracture
(%)
32 (9.61) 39 (11.82) 36 (11.04) 35 (10.64) 0.832 0.997
Incident fracture 5 years 20/323 (6.2) 12/320 (3.7) 21/318 (6.6) 22/323 (6.8) 0.320 0.461
Spine average BMD 0.921 ± 0.168 0.932 ± 0.164 0.933 ± 0.155 0.915 ± 0.168 0.437 0.696 0.375
Spine average T-score −1.13 ± 1.59 −1.03 ± 1.54 −1.01 ± 1.46 −1.18 ± 1.58 0.424 0.707 0.367
Spine average TBS 1.322 ± 0.104 1.326 ± .0105 1.319 ± 0.103 1.319 ± 0.098 0.773 0.509 0.525
Femoral neck BMD 0.724 ± 0.113 0.727 ± 0.114 0.741 ± 0.112 0.727 ± 0.199 0.234 0.424 0.391
Femoral neck T-score −1.13 ± 1.01 −1.096 ± 1.02 −0.97 ± 1.00 −1.10 ± 1.07 0.223 0.397 0.361
Femur total BMD 0.848 ± 0.118 0.857 ± 0.121 0.869 ± 0.119 0.845 ± 0.112 0.046 0.945 0.979
Femur total T-score −0.77 ± 0.96 −0.69 ± 0.98 − 0.59 ± 0.97 −0.79 ± 0.92 0.043 0.913 0.987
Results are expressed as number of participants (%) or as mean ± standard deviation. Statistical analysis performed using chi-square for categorical variables and
ANOVA for continuous variablesa, p of trendb and after multiple adjustmentc (age, BMI, smoker, diabetes, alcohol, calcium, HRT)
Table 5 Bone parameters (fracture, BMD and TBS) according to quartiles of tumour necrosis factor α
First Second Third Fourth P-
valuea
P-value trend
testb
P-value
adjustedc
N 330 331 329 329
TNF-α, median [IQR] 1.74 [1.08–
2.19]
3.71 [3.19–
4.29]
6.18 [5.40–
6.99]
12.23 [9.77–
20.17]
Traumatic fracture (%) 84 (25.4) 95 (28.7) 86 (26.1) 81 (24.6) 0.662 0.500
Major osteoporotic fracture
(%)
28 (8.4) 40 (12.0) 36 (10.9) 38 (11.5) 0.456 0.436
Incident fracture 5 years 23/325 (7.1) 13/320 (4.1) 13/320 (4.1) 26/320 (8.1) 0.054 0.678
Spine average BMD 0.930 ± 0.168 0.920 ± 0.156 0.920 ± 0.164 0.931 ± 0.168 0.730 0.893 0.315
Spine average T-score −1.05 ± 1.58 −1.13 ± 1.47 −1.14 ± 1.55 −1.02 ± 1.57 0.697 0.814 0.342
Spine average TBS 1.326 ± 0.102 1.318 ± 0.099 1.316 ± 0.108 1.326 ± 0.101 0.451 0.981 0.816
Femoral neck BMD 0.738 ± 0.118 0.718 ± 0.114 0.729 ± 0.115 0.734 ± 0.111 0.152 0.937 0.755
Femoral neck T-score −1.00 ± 1.06 −1.17 ± 1.02 −1.08 ± 1.03 − 1.04 ± 1.00 0.176 0.942 0.759
Femur total BMD 0.864 ± 0.121 0.842 ± 0.113 0.857 ± 0.117 0.856 ± 0.119 0.108 0.817 0.557
Femur total T-score −0.64 ± 0.99 −0.82 ± 0.91 −0.69 ± 0.96 −0.70 ± 0.97 0.109 0.806 0.543
Results are expressed as number of participants (%) or as mean ± standard deviation. Statistical analysis performed using chi-square for categorical variables and
ANOVA for continuous variablesa, p of trendb and after multiple adjustmentc (age, BMI, smoker, diabetes, alcohol, calcium, HRT)
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association was detected, no information on patients with
inflammatory disease was given and chronic inflammatory
diseases could be confounding factors.
Regarding the lumbar spine BMD, discordant results
could be explained by the presence of degenerative dis-
ease, very common in people older than 60 to 65 years
[34]. Spinal osteoarthritis (OA) is known to increase
BMD in the lumbar spine [34–36]; and it has been re-
ported that individuals with OA have significantly higher
hs-CRP levels [20]. Therefore, it is possible that OA
changes associated with aging may have confounded the
association between hs-CRP levels and spine BMD.
However, we cannot explain the absence of any correl-
ation between TBS and hs-CRP by degenerative diseases,
since Padlina et al. [34] showed that TBS is not affected
by degenerative diseases like OA. Moreover, we cannot
compare our results to those of other studies, in the ab-
sence of published data between hs-CRP and bone
microarchitecture in females. Rolland et al. suggested an
association between higher hs-CRP and poor trabecular,
but not cortical microarchitecture in the distal radius, as
assessed by peripheral quantitative computed tomog-
raphy (pQCT) in men age 72 and older, but not in youn-
ger men [37]. Watanabe et al. demonstrated that TBS
was associated with hs-CRP levels in 61 Japanese male
COPD patients [38], but there are no published data on
cytokines in patients without a chronic inflammatory
disease and TBS.
Relationship between bone imaging and structure
parameters and IL-1β
Our study identified no difference in fractures, BMD or
TBS, in the different quartiles of IL-1β. Interleukin 1 is a
prototypic proinflammatory cytokine that regulates a wide
variety of cellular and tissue functions. There are two
forms of IL-1: IL-1α and IL-1β. Several data suggest the
involvement of IL-1 in bone destruction under patho-
logical conditions, including RA and OP. Iwakura et al.
[39] demonstrated that IL-1 also plays an important role
in physiological bone metabolism in mice. In particular,
IL-1 directly activates RANK (receptor activator of nuclear
factor--kB) inducing RANKL ligand and promoting osteo-
clastogenesis. However, Bab et al. found conflicting results
when examining the role of IL-1 in vivo [40].
Kim et al. [41] found no significant differences in BMD
(lumbar spine or proximal femur) or in serum bone pa-
rameters levels across the IL-1α or IL-1β genotypes. Lang-
dahl et al. [42] found that an 86-base pair repeat
polymorphism in the IL-1 receptor antagonist (IL-1ra)
gene was associated with an increased risk of osteoporotic
fractures. Other polymorphisms in the IL-1ra and IL-1β
genes were not associated with osteoporotic fractures,
BMD, or bone turnover.
Relationship between bone imaging and structure
parameters and IL6
Our study showed no difference in fractures, BMD, or
TBS across the different quartiles of IL6. Interleukin 6 is a
multifunctional cytokine that plays a pivotal role in the
regulation of immune responses and bone marrow
hematopoiesis. It is also involved in the regulation of oste-
oclastogenesis and bone resorption in many pathophysio-
logical conditions. It exerts its biological activity by
binding to specific receptors; only a small fraction is free
[19]. The IL-6 receptor consists of two subunits: the
ligand-binding low-affinity component soluble receptor
(sIL-6R) and a signal transducing receptor (gp130) [43].
The literature on IL-6 is inconsistent. In one study that
included men and women, Ding et al. found that IL-6 was
consistently associated with reduced BMD [12]. Sansoni
et al. found, after multiple regression, that only sIL-6R,
but not IL-6, was a significant determinant of BMD in
postmenopausal women [43]. Cauley et al. [44] found a
higher mean concentration of IL6 in men who had experi-
enced a hip fracture relative to those without, but the
same association was not apparent in women [19]. Inter-
leukin 6 is the only cytokine that shows diurnal variation
and reaches its lowest point in the morning [45]. More-
over, it has been reported that circulating IL-6 concentra-
tions across a 24-h time period and a transient increase of
IL-6 level during the sleep period can be attributed, at
least in part, to effects of having an IV catheter and/or dif-
ficulties with blood drawing [46]. The difficulties with re-
producible measurements of IL-6 could explain the
discrepancies in the literature.
Relationship between bone imaging and structure
parameters and TNF- α
Our study revealed no difference in fractures, BMD or TBS
in the different quartiles of TNF-α. TNF-α, a multifunc-
tional cytokine mainly produced by activated macrophages,
is one of the most potent osteoclastogenic cytokines pro-
duced in inflammation. TNF-α is responsible for stimulat-
ing osteoclastic bone resorption in vitro, as well as in vivo.
TNF-α is associated with various cell signaling systems via
2 types of cell surface receptor, namely TNFR I (p55) and
TNFR II (p75). In pathological circumstances, it has been
shown that TNFR I promotes osteoclastogenesis, whereas
TNFR II acts as an inhibitor [47].
The Health Aging and Body Composition Study, which
included 2985 men and women > 70 years old, showed
that the fracture incidence increases with the cytokine
level. Moreover, subjects in the highest level of TNF-α
had a 33% increased risk of fracture, independent of other
risk factors [19]. However, no information on patients
with inflammatory disease was given, and the results were
not adjusted for BMI. The discrepancy with our results
could be explained by the short half-life of TNF-α in the
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circulation. Increases in serum concentrations of TNF-α
are usually transient, whereas elevations in serum TNF-α
soluble receptors are more constant [19].
In the present study, the method of cytokine measure-
ment was similar. Venous blood samples also were
drawn in the fasting state, allowed to clot and then kept
at − 80 °C before assessment and sent in dry ice to the
laboratory. Our lower limit of detection for TNF-α was
0.2 pg/ml [24].
Strengths and limitations
To our knowledge, this is currently the largest
population-based sample in which the associations be-
tween bone parameters (prevalent and incident fractures,
BMD at two different sites and TBS) and inflammatory
cytokines (hs-CRP, IL-6, IL-1β and TNF-α) within the
normal range have been assessed in postmenopausal
women, excluding participants with a chronic inflamma-
tory disease. However, we should also mention some
limitations. First, the duration was only 5 years and we
measured circulating cytokines in the serum, but the
highest concentrations of cytokines may be found in the
bone microenvironment [19]. Secondly, we did not ad-
just our results to physical activity or medication use.
For example, Nonsteroidal anti-inflammatory drugs
(NSAIDS) or betablockers have a well-known impact on
bone and could affect inflammatory parameters [19],
and statins could inhibit TNF-α production and release
and, thereby, inhibit IL-6 and CRP production [6].
Thirdly, we measured IL-6 and not sIL-6R or gp130,
which are more stable than IL-6. The same applies for
TNF-α (we did not measure TNF sRI or TNF sRII) and
IL-1β (we did not measure IL-1ra). Fourthly, we did not
measure bone serum markers (such as β Crosslaps) or
vitamin D levels in our study.
Our study gives important information about post-
menopausal Caucasian women, but cannot be general-
ized to men or to other ethnicities. Finally, we
hypothesize that BMI itself could explain the link be-
tween aging and bone imaging and structure parameters
degradation. Aging is associated with changes in body
composition, including a decrease in lean mass and an
increase in total-body fat, particularly abdominal adipose
tissue [6]. In octogenarians, investigators have found that
plasma levels of TNF-α are correlated linearly with sys-
temic levels of leptin, which is proportional to the
amount of fat mass [6]. In our study, the oldest women
had the highest BMI.
Conclusions
In conclusion, in this large population-based cohort of
postmenopausal women, we did not find a relation be-
tween so-called “inflammaging” and bone imaging and
structure parameters, measured in terms of prevalent
and incident fractures, lumbar spine and hip BMD or
TBS. Future studies in this area should probably include
body composition data.
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